Skip to content

pharmaceuticals.co.nz

Drugs, medicines and medical news
Main navigation

Category: Boehringer Ingelheim

SMC accepts Boehringer/Lilly’s Jardiance for CKD within NHS Scotland

SMC accepts Boehringer/Lilly’s Jardiance for CKD within NHS Scotland
p p Read More

The serious, progressive kidney disease affects nearly 850 million people worldwide

July 9, 2024 Boehringer Ingelheim, chronic kidney disease, EMPA-KIDNEY, empagliflozin, Jardiance, News, NHS Scotland, Scottish Medicines Consortium

Boehringer Ingelheim and Ochre Bio partner on liver disease in deal worth over $1bn

Chronic liver disease and associated cirrhosis account for one million deaths every year

April 23, 2024 Boehringer Ingelheim, chronic liver disease, metabolic diseases, metabolic dysfunction-associated steatohepatitis, News, Ochre Bio

New clinical study to advance development of treatments for liver cirrhosis

The £30m ADVANCE study is the most extensive study into liver disease worldwide

January 10, 2024 Accelerating Discovery: Actionable NASH Cirrhosis Endpoints, Boehringer Ingelheim, Liver cirrhosis, Newcastle University, News, University of Edinburgh
Proudly powered by WordPress | Theme: Hive Lite by Pixelgrade.
Footer navigation
  • Privacy Policy